These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 31886335

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots.
    Ullal AJ, Millington DS, Bali DS.
    Mol Genet Metab Rep; 2014; 1():461-464. PubMed ID: 27896123
    [Abstract] [Full Text] [Related]

  • 23. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.
    Schrover R, Evans K, Giugliani R, Noble I, Bhattacharya K.
    Orphanet J Rare Dis; 2017 Apr 26; 12(1):78. PubMed ID: 28441951
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Transnasal adenoidectomy in mucopolysaccharidosis.
    Harrison R, Schaefer S, Warner L, Mercer J, Jones S, Bruce I.
    Int J Pediatr Otorhinolaryngol; 2018 Aug 26; 111():149-152. PubMed ID: 29958599
    [Abstract] [Full Text] [Related]

  • 26. Mucopolysaccharidoses type I and IVA: clinical features and consanguinity in Tunisia.
    Khedhiri S, Chkioua L, Bouzidi H, Dandana A, Ben Turkia H, Miled A, Laradi S.
    Pathol Biol (Paris); 2009 Jul 26; 57(5):392-7. PubMed ID: 18584975
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.
    Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tylee KL, Wynn RF, Wijburg FA, Jones SA, Bruce IA, Bigger BW.
    Orphanet J Rare Dis; 2015 Apr 10; 10():42. PubMed ID: 25887468
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Functional capacity evaluation of patients with mucopolysaccharidosis.
    Guarany NR, Schwartz IV, Guarany FC, Giugliani R.
    J Pediatr Rehabil Med; 2012 Apr 10; 5(1):37-46. PubMed ID: 22543891
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
    Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, Parini R, Hughes D, Pastores GM, Lau HA, Al-Sayed MD, Raiman J, STRIVE Investigators, Yang K, Mealiffe M, Haller C.
    Mol Genet Metab; 2015 Feb 10; 114(2):178-85. PubMed ID: 25284089
    [Abstract] [Full Text] [Related]

  • 36. Enzyme replacement therapy: efficacy and limitations.
    Concolino D, Deodato F, Parini R.
    Ital J Pediatr; 2018 Nov 16; 44(Suppl 2):120. PubMed ID: 30442189
    [Abstract] [Full Text] [Related]

  • 37. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
    Sawamoto K, Tomatsu S.
    Int J Mol Sci; 2019 Aug 24; 20(17):. PubMed ID: 31450640
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.